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Cyclophilins (Cyps) are a group of peptidyl-prolyl cis/trans isomerases that play crucial
roles in regulatory mechanisms of cellular physiology and pathology in several
inflammatory conditions. Their receptor, CD147, also participates in the development
and progression of the inflammatory response. Nevertheless, the main function of Cyps
and their receptor are yet to be deciphered. The release of CypA and the expression of the
CD147 receptor in activated T lymphocytes were already described, however, no data are
available about other Cyps in these cells. Therefore, in the present work intra and
extracellular CypA, B and C levels were measured followed by induced inflammatory
conditions. After activation of T lymphocytes by incubation with concanavalin A, both intra
and extracellular Cyps levels and the CD147 membrane receptor expression were
increased leading to cell migration towards circulating CypA and CypB as
chemoattractants. When CypA was modulated by natural and synthetic compounds,
the inflammatory cascade was avoided including T cell migration. Our results strengthen
the relationship between CypA, B, and C, their receptor, and the inflammatory process in
human T lymphocytes, associating CypC with these cells for the first time.
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Cyclophilins (Cyps) belong to a subgroup of proteins called immunophilins. This well-studied
family is highly conserved in all organisms and possesses peptidyl-prolyl cis-trans isomerase
(PPIase) activity. Cyps are involved in cell signaling, trafficking, protein folding, and
transcription (1). The PPIase activity of Cyps is inhibited by the potent immunosuppressant
cyclosporine A (CsA) produced by the fungus Tolyplocadium inflatum (2). Furthermore, some
Cyps, namely CypA, B and C among others, have been implicated in inflammatory-related diseases
(3, 4). Inflammation is a complex process, in its development, immune cells, such as monocytes,
macrophages and T lymphocytes are recruited and accumulated into tissues (5). This recruitment
and trafficking are key steps during the activation of the inflammatory response. In this process,
extracellular CypA act as a chemotactic agent for leukocytes. Upon inflammatory conditions,
endothelial cells (ECs), vascular smooth muscle cells, inflammatory lesions, and monocytes generate
high amounts of CypA. In this way, CypA is released and begins a chemotactic response fororg March 2021 | Volume 12 | Article 6091961
Gegunde et al. CypA, B and C Roleleukocytes (6). Extracellular CypA, at the same time, promotes
inflammatory responses, such as ROS production, extracellular
signal-regulated kinase (ERK) 1/2 phosphorylation, DNA
synthesis, and vascular smooth muscle cell proliferation (7).
Furthermore, high levels of CypA are found in synovial fluids
from patients with rheumatoid arthritis, in plasma from patients
with type 2 diabetes, and serum from patients with sepsis (8, 9).
CypB also possesses proinflammatory properties and is secreted
by several cells. This immunophilin plays a principal role in ER
redox homeostasis. High CypB levels are found in inflammatory
processes, like sepsis and rheumatoid arthritis, as well as CypA.
Besides, platelet adhesion to collagen and the neutrophil
chemotaxis is promoted by CypB (10). Furthermore, CypA
and B expression is augmented in the cytosol of T lymphocytes
from patients with coronary artery disease (CAD) (11). Less is
known about the role of CypC, albeit this immunophilin
participates in redox ER homeostasis and has been linked to
macrophage activation (12). Moreover, recent studies described
high CypC serum levels in patients with acute CAD when
compared with controls. In this sense, this immunophilin was
proposed as a CAD biomarker (4, 13). CAD is an inflammatory-
based pathology, whereby CypA and B, along with CypC also
play a relevant role (13–15).
Extracellular CypA and B bind to the CD147 membrane
receptor and modulate inflammatory pathways (10, 16). CD147
is a type I transmembrane glycoprotein that belongs to the
immunoglobulin superfamily (17) . This receptor is
overexpressed in activated T and B lymphocytes, neutrophils,
monocytes, macrophages, and dendritic cells, participating in the
immune and inflammatory response (18). Besides, chemotaxis,
phosphorylation of ERK 1/2 and cell signaling are mediated by
Cyps through CD147 (19). Moreover, the extracellular
interaction of CypA/CD147 is upregulated in inflammatory
and autoimmune diseases (11, 18). Consequently, there is a
clear interconnection between CypA, CypB, the CD147
receptor, and inflammatory-related diseases. T lymphocytes are
critical players in the progression of the inflammatory response.
Although the activation of these cells involves several well-
known pathways promoting proinflammatory mediators
release, Cyps role is still undefined. CD147 receptor expression
and CypA release were described in T cells upon inflammatory
conditions (6, 20). However, the intracellular expression of thisFrontiers in Immunology | www.frontiersin.org 2protein as well as CypB or C profile were not before studied in
these conditions.
The modulation of Cyps with specific drugs has been used to
better understand the inflammatory response. In this way, recent
data have shown that natural gracilins and synthetic gracilin A
(GraA)-analogues can bind certain Cyps and inhibit the
calcineurin phosphatase activity, in the same way as the well-
known CypA inhibitor CsA (20–22). Gracilins, diterpenes
derivatives extracted from the sponge Spongionella gracilis,
have shown neuroprotective, antioxidant, and anti-
inflammatory capacities through their binding affinities toward
CypA and/or CypD (22–24). Also, these compounds modulate
the expression of CD147 on activated T lymphocytes (20, 22).
Thus, two synthetic GraA-analogues, bis-acetoxy furanoses,
compounds 1 and 2 (Figure 1), are inhibitors of CypA (21).
They showed kinetic equilibrium dissociation constants (KD)
values in the nanomolar range as measured by plasmon
resonance experiments (Table 1) (21, 22). Moreover, these
small molecules decrease pro-inflammatory mediators release,
inhibit the calcineurin phosphatase activity, target the
translocation of pro-inflammatory proteins and promote
antioxidative mechanisms through CypA modulation (21, 25).
Therefore, they showed interesting anti-inflammatory capacities
and are valuable tools to improve knowledge about the role of
Cyps in inflammatory conditions.
In this context, in the present study CypA, B and C levels and
their association with the CD147 receptor upon inflammatory
conditions are studied in human T lymphocytes as well as their
modulation with natural and synthetic gracilins.A B C
FIGURE 1 | Natural gracilin and two synthetic analogues structures. Compound 1 (A), 2 (B), and Gracilin L (C).TABLE 1 | Kinetic equilibrium dissociation constant (KD) values for binding of
Spongionella derived compounds and CsA to CypA.
KD (nM) Calcineurin inhibition (%) IL-2 release (%)
Gracilin L 24.85 ± 6.83 ≈ 10 71.8 ± 11.6
Compound 1 5.34 ± 1.68 22.3 ± 6.1 44.5 ± 2.15
Compound 2 7.67 ± 1.61 31.0 ± 3.4 36.1 ± 5.9
Cyclosporin A 6.83 ± 1.1 17.3 ± 4.5 66.75 ± 8.25March 2021 | Volume 12Inhibition of calcineurin phosphatase activity expressed in percentage of control cells. IL-2
inhibition is expressed in the percentage of control cells. For calcineurin and
IL-2 experiments, cells were treated with GraL (1 mM), compounds 1, 2 (0.1 µM), or CsA
(0.2 µM) for 2 h and then were stimulated with Con A (50 mg/mL) for 48 h.| Article 609196
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Chemicals and Solutions
The natural compound Gracilin L was kindly donated by Dr. Marcel
Jaspars from the University of Aberdeen, Scotland, UK. The synthetic
compounds, 1 and 2, were kindly donated by Dr. Romo group from
the Department of Chemistry and Biochemistry, Baylor University,
Texas, US. The sponge-derived GraA was used to obtain bioactive
small molecules, compound 1 and 2, through pharmacophore-
directed retrosynthesis (PDR) as described previously (21).
Human Cyclophilin A ELISA kit (CSB-E09920H), Human
Cyclophilin B ELISA kit (CSB-E11218H) and Human Peptidyl-
Prolyl cis-trans Isomerase C (PPIC) Elisa kit (CSB-
EL018473HU) were purchased from Cusabio (Madrid, Spain).
FITC anti-human CD147 was from Immunostep (Salamanca,
Spain). Percoll was obtained from GE Healthcare (Madrid,
Spain). The human Pan T cell Isolation Kit and the
monoclonal antibody to human CD3, clone BW264/56, FITC
were purchased from Miltenyi Biotec (Germany). The
composition of phosphate buffer saline (PBS) solution used for
human T lymphocytes purification was (in millimolar) 137 ClNa,
8.2 Na2HPO4, 3.2 KCl, 1.5 KH2PO4 and 2 EDTA, pH 7.2-7.4.
The composition of Umbreit saline solution was (in millimolar)
119 NaCl, 5.94 KCl, 22.85 NaHCO3, 1.2 MgSO4, 1.2 NaH2PO4,
and 1 CaCl2. Glucose 1 g/L was added to the medium. Roswell
Park Memorial Institute (RPMI) medium, Foetal bovine serum
(FBS), penicillin/streptomycin, SuperSignal west pico,
SuperSignal west femto, anti-Actin monoclonal antibody (cat.
No. #ACTN05 (C4), lot. #SK2474691D), anti-CypC antibody
(cat. No. #PA5-69299, lot. #TD2552443D) were obtained from
Thermo Fisher Scientific (Madrid, Spain). Anti-PPIA polyclonal
antibody (cat. No. E-AB-15306, lot. DK0674), anti-CypB
antibody (cat. E-AB-22123, lot. AC0235), were bought in
Elasbscience (Madrid, Spain). Polyacrylamide gels and
molecular weight marker Precision Plus Protein Standards
Kaleidoscope were obtained from Bio-Rad (Barcelona, Spain).
Protease Inhibitor Complete Tablets and Phosphatase Inhibitor
Cocktail Tablets were from Roche (Madrid, Spain). Cyclosporine
A (purity ≥98.5%), Chemotaxis 5 mm 96-Well Cell Migration
Assays (ECM512), Percoll (GE17-0891-01), Polyvinylidene
difluoride (PVDF) membrane, Bovine Serum Albumin (BSA),
endoplasmic reticulum isolation kit (cat# ER0100), and the rest
of chemicals and reagents were obtained from Sigma-Aldrich
(Madrid, Spain). Recombinant human cyclophilin A protein
(active) (ab86219) was purchase from Abcam (Germany).
Recombinant human cyclophilin B protein (active) (Cat. No.
ABIN1304473) was bought in Antibodies-online. Stock solutions
of drugs were done in dimethyl sulfoxide (DMSO). The amount
of DMSO added to the cells was always lower than 0.01%. The
same amount of vehicle is added to control cells.
Human T Lymphocytes Isolation
Volunteers without known inflammatory-related disease or other
conditions, were enrolled in the present study. This study was
reviewed and approved by the institutional and regional ethical
boards according to the Declaration of Helsinki (Reference: 2016/Frontiers in Immunology | www.frontiersin.org 3508, Approved date: December 19, 2016). All participants have
given their written informed consent before the study began.
Peripheral blood for T lymphocytes isolation was obtained from
each subject using tubes with EDTA (BD vacutainer blood
collection tubes). The human T lymphocytes were isolated as
described before (11). Briefly, 3 mL of isotonic percoll (57.5%)
were placed at the bottom of a 10 mL tube, then 4 mL of diluted
blood was added to the surface of the isotonic percoll. The tubes
were centrifuged at 3000 rpm for 25 min. T lymphocytes
appearing in the interface were rinsed with PBS-EDTA and
centrifuged at 1500 rpm for 10 min. Pan T cell Isolation kit was
used to purify T cells from this population according to the
manufacturer’s instructions. The purity of T lymphocytes
obtained was ≥ 98%. The cell purity was measured by flow
cytometry, using a monoclonal antibody to human CD3 labeled
with FITC. The population of T cells obtained from one subject
was used for a single replica (biological replica) and was measured
by triplicate or duplicate (technical replica). Therefore, T cells
from three different donors were used in each experiment.
T Lymphocytes Culture and Activation
Purified T lymphocytes from control subjects were maintained in
RPMI supplemented with 10% FBS, penicillin (100 U/mL), and
100 mg/mL streptomycin at 37°C in a humidified atmosphere of
5% CO2 and 95% air. 2 x 10
6 human T lymphocytes were seeded
in a 48-well plate in a volume of 400 mL. Cells were pre-treated
with GraL (1 mM), compound 1, compound 2 (0.1 mM) or CsA
(0.2 mM) for 2 hours. Then, these cells were activated with Con A
(50 mg/mL) for 48 hours and then were used for experiments of
ELISA, westerns blot and flow cytometry (20, 21). In each
experiment unstimulated cells are used as control. These cells
were incubated with the same amount of vehicle than treated cells.
Measurement of Extracellular Cyclophilin
A, B, and C Levels
Levels of CypA, B, and C were measured in a culture medium
obtained from T lymphocytes. After compounds pre-treatment
and Con A activation cells were centrifuged at 2000 rpm, at 4°C
for 5 min. Cyps measurements were done in the media collected,
using ELISA kits following the manufacturer’s instructions as
previously described (4). The optical density of each well was
obtained using a spectrophotometer microplate reader (Sinergy 4
de Biotek). All samples were run in duplicate, and the
concentrations were calculated using a standard curve. The intra
and inter-assay coefficients of variation of the ELISA kits were
<10%. No cross-reactivity was observed between Cyp antibodies.
CD147 Receptor Expression in T
Lymphocytes
The CD147 receptor expression was assessed in treated cells as
described before (20). In brief, 1 x 106 washed T cells were
suspended in 50 mL of PBS/BSA and were incubated with 20 mL
of FITC Anti-Human CD147 for 90 min in darkness at 4°C and
300 rpm. After that, cells were washed and resuspended in
100 mL of PBS with 1% of paraformaldehyde, then were
analyzed by flow cytometry technique. The IDEASMarch 2021 | Volume 12 | Article 609196
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obtained from the measurements of the fluorescence intensity.
ER and Golgi Apparatus Isolation
Isolation of the ER and Golgi apparatus was performed in T
lymphocytes with a commercial kit (Sigma endoplasmic
reticulum isolation kit) according to the manufacturer’s
instructions. In brief, cells were suspended in a hypotonic
extraction buffer. After 20 min incubation on ice, cells were
centrifuged at 600 g for 5 min and 4°C, and the supernatant was
discarded. Then isotonic extraction buffer was added, and the
homogenates were centrifuged at 1,000 x g for 10 min and 4°C.
The supernatant was subjected to a series of centrifugation steps
and then the microsomal fraction containing the ER and Golgi
apparatus was obtained and used for western blot analysis.
Western Blot Analysis
Western blot was performed to determine the expression of
CypA and CypB in the cytosol of T cells as previously described
and as well as the expression of CypC in the Golgi apparatus and
ER (25). In brief, to extract the cytosolic proteins, the pellet was
suspended for 15 min in 100 mL of ice-cold hypotonic lysis, then
5 mL of Triton X-100 was added and centrifuged for 10 min at 4°C
and 3000 rpm. The supernatant was collected as the cytosolic
fraction. Protein cytosol concentration was determined by Direct
Detect (Millipore). CypC was studied in ER and Golgi-apparatus
as described above. 10 mg of total protein of cell lysates were
resolved on a 4-20% polyacrylamide gel and transferred onto
PVDF membrane for electrophoresis. To determine the protein
size Precision Plus Protein Standards Kaleidoscope molecular
weight marker was used. Afterward, membranes were blocked
with 0.5% BSA diluted in wash buffer and antibody incubation
was performed using SNAP i.d. protein detection system. The
immunoreactive bands were analyzed using the Supersignal
West Pico or Supersignal West Femto and the Diversity
GeneSnap software (Syngene). CypA was detected with anti-
PPIA (1:2000), CypB was measured with anti-CypB (1:2000) and
CypC was analyzed with anti-CypC antibody (1:1000). The
signal was normalized by that of b-actin (1:2000). Cross-
reactivity between Cyp antibodies was checked with pure Cyps
and no interactions were observed (see Supplementary Material,
Figures S1A–C). Uncropped images of western blot experiments
showed in Figures 2D–F and 3D–F are showed in supplementary
material (Figures S2–S5).
Chemotaxis Assay
Purified human T lymphocytes were used to carry out the
chemotaxis cell migration experiments using the Chemotaxis
5 mm 96-Well Cell Migration Assay as described before (20). In
this commercial kit, the number of migratory cells is quantified by
using a fluorescent CyQuant GR Dye. The assay was performed
following the manufacturer’s instructions. Briefly, 150 mL of
serum-free RPMI culture medium in the presence or absence of
chemoattractant (50 ng/mL CypA or 5 ng/mL CypB) were added
to the 96-well feeder tray plate. Then, untreated, or treated cells
(200.000 per condition and 100 mL of culture media without FBS)
were placed on the insert membrane for 24 h at 37°C and 5% CO2.Frontiers in Immunology | www.frontiersin.org 4After 24 hours, migratory cells were incubated for 15 min at room
temperature with Lysis buffer containing the CyQuant GR Dye.
Afterward, the fluorescence of lysed T lymphocytes was measured
in a spectrophotometer plate reader at 480 nm excitation and
520 nm emission.
Statistical Analysis
Results were expressed as mean ± SEM of a minimum of three
independent experiments (three biological replicates) and were
performed by duplicate or triplicate (technical replicates).
Comparisons were analyzed using ANOVA statistical analysis
followed by post hoc Dunnet’s t-test. P values < 0.05 were
considered statistically significant.RESULTS
Upon inflammatory conditions, CypA secretion from T
lymphocytes was previously described (6, 20, 26). Nevertheless, no
data are available regarding intracellular CypA expression or CypB
and C levels in these conditions. So, our initial premise was to
check Cyps profile in Con A-stimulated T cells. Purified human T
lymphocytes were activated with Con A, a known inflammatory
stimulator, for 48 hours, and intra and extracellular CypA levels
were measured. As was expected Figure 2A, the release of CypA
was more than two times higher in cells treated with Con A
compared with untreated cells (p < 0.05). Moreover, as Figure 2D
shows, in these conditions, the intracellular CypA expression was
also raised (p < 0.001), more than three times. Then, CypB and C
were measured in activated T lymphocytes. As Figure 2B shows,
the release to the medium of CypB was twice higher on Con A-
treated cells. Besides, the intracellular CypB expression was
significantly increased in stimulated T cells comparing with
untreated cells (Figure 2E, p < 0.01). As happened with CypA
and B, the liberation of CypC was also significantly elevated
(Figure 2C). The CypC levels were significantly increased in the
activated T lymphocyte’s medium than in untreated cells (p <
0.01). Also, as Figure 2F shows, the intracellular expression of
CypC was augmented, 40%, in cells treated with Con A (p < 0.05).
Therefore, in addition to CypA and B, upon inflammatory
conditions, CypC is also produced and released by activated
T lymphocytes.
To better understand the relationships between CypA, B, and C
under inflammatory conditions, CypA selective inhibitors were used
in activated T cells, and Cyps profiles were checked again. For this
purpose, the natural GraL, two synthetic GraA-analogues,
compounds 1 and 2, and CsA were tested in Con A-stimulated
human T lymphocytes, then, Cyps release (Figures 3A–C) and their
intracellular expression (Figures 3D–F) were measured. In the
present study, we have focused on these compounds because as
Table 1 shows, they have shown high affinities by CypA (nM range
of KD), inhibition of calcineurin phosphatase activity (10-30%) and
inhibition of interleukin (IL)-2 release in the same level as CsA (21,
22). Moreover, these synthetic compounds have interesting anti-
inflammatory and neuroprotective activities in the same way as
natural gracilins (20–22, 24, 27). In the following experiments, the
concentration of 1 mM of GraL, 0.1 mM of compounds 1 and 2, andMarch 2021 | Volume 12 | Article 609196
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greatest anti-inflammatory activity without compromising cell
viability in previous experiments, both in T lymphocytes and glial
cells (20, 21, 25). As shown in Figure 3A, the liberation of CypA was
significantly reduced, when T cells were preincubated with
compound 1 (p < 0.05), compound 2 (p < 0.05) or GraL (p <
0.001). The CypA liberation was also inhibited, by CsA, as it was
already described (20). As Figure 3B shows, the CypB levels were
highly reduced in the medium of stimulated T cells pre-treated with
compound 1 (p < 0.05), 2, GraL and CsA (p < 0.01). Furthermore, in
Figure 3C, CypC release from T lymphocytes was also significantly
decreased by natural GraL and the two synthetic compounds (p <
0.05). CsA significantly modifies CypC release, with the lower
effect. Therefore, when CypA is modulated in activated T cells,
extracellular CypB and C levels are restored near to non-
inflammatory conditions. Next, intracellular CypA, B and C
expression were also tested. As Figure 3D shows, CypA
expression was reduced in activated T cells by compounds 1, 2,
or GraL pre-treatments, reaching unstimulated cell levels
(p < 0.05). Intracellular CypA expression was also reduced by
CsA (p < 0.05). Furthermore, the intracellular CypB expression wasFrontiers in Immunology | www.frontiersin.org 5significantly reduced to control values after pre-treatment of Con
A-stimulated T cells with Spongionella derivatives, or CsA (Figure
3E, p < 0.01). Moreover, it is important to highlight that
intracellular CypA and B levels follow the same profile (Figures
3D, E). Finally, as Figure 3F shows, compounds 1 and 2
significantly diminished CypC intracellular expression in
activated T lymphocytes (p < 0.01, p < 0.05), while the pre-
treatment with GraL or CsA did not modify intracellular CypC
levels. Thus, the modulation of CypA levels with Spongionella-
derived compounds substantially affects CypA, B, and C
profiles. These compounds are more potent than the classical
immunosuppressive CsA.
CD147 is the extracellular receptor for CypA and B and is
overexpressed in several inflammatory pathologies. Moreover,
the membrane expression of this receptor is controlled by these
Cyps (10, 28, 29). Hence, our next step was to check if CypA
modulation by natural and synthetic compounds affects receptor
expression. As Figure 4 shows, the CD147 receptor is at least
20% expressed in T cell surface after Con A stimulation versus
6% in the surface of untreated cells. That is, the receptor was
three times more present on the cell surface of stimulated cellsA B C
D E F
FIGURE 2 | Intra and extracellular CypA, B, and C levels in human T lymphocytes stimulated with Con A Cells were treated with Con A (50 mg/mL) for 48 h. CypA (A),
CypB (B), and CypC (C) levels were measured by ELISA in the medium of T lymphocytes. The intracellular expression of CypA (D), CypB (E), and CypC (F) was measured
by western blot in cytosolic lysates of T lymphocytes. Band intensity was normalized by b-actin. Data are the result of average ± SEM (n = 3). The values are shown as the
difference between cells treated with Con A and untreated cells, *p < 0.05, *p < 0.01 and ***p < 0.001. One-way ANOVA test with Dunnet’s post hoc analysis and Student´
s t-test were used for statistical analysis.March 2021 | Volume 12 | Article 609196
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receptor expression on activated T cells is in line with the results
described before (20). However, the receptor expression was
halved in the presence of compounds 1, 2, and GraL (p < 0.01).
Also, the expression of CD147 in the membrane of activated T
lymphocytes was significantly reduced after CsA treatments (p <
0.01). Therefore, CypA modulation decreased the CD147
expression on activated T lymphocytes.
Extracellular CypA and B act as chemoattractants for T cells
through their interactions with the CD147 membrane receptor (3,
10, 30). As we previously described, Con A-activated human T
lymphocytes canmigrate towards CypA, and this effect was blocked
by natural gracilins or CsA treatment (20). However, the role of
CypB in this cellular model of inflammation as well as the effect of
selective CypA modulation is unknown. Therefore, our final step
was to check T cell migration under these conditions performing a
chemotaxis assay. After 48 hours of Con A-treatment, cells were
placed in the insert membrane of the migration chamber, while in
the feeder tray CypA or B were used as chemoattracting agents.
After 24 hours the number of cells migrated was measured. As
Figures 5A, B show, in control conditions (non-stimulated cells
and absence of chemoattractants) around 40,000 cells freely migrate
from the upper to the bottom chamber. When CypA (50 ng/mL)
was added to the bottom chamber, Figure 8a , 60,020 ± 2,846 cells
were attracted. In those conditions, as expected, cell migration wasFrontiers in Immunology | www.frontiersin.org 6increased by 40% (94,638 ± 1,230 cells) when T cells were
previously activated with Con A. If CypA pathway was inhibited
by pre-treatment with compound 1, 2, GraL, or CsA, the migration
promoted by Con A was significantly avoided (p < 0.05). Then,
CypB (5 ng/mL) was added to the bottom of the chamber to check
its efficiency as a T cell chemoattractant. We used this amount
because extracellular CypB levels are usually 10 times lower than
CypA in inflammatory conditions (4, 13, 31). As Figure 5B shows,
when CypB was present, 56,229 ± 3,622 of untreated cells migrated
to the bottom chamber. When T cells were Con A-stimulated, the
migratory cell number was increased (72,049 ± 0,896; p < 0.05). In
these conditions, T cell migration was avoided when CypA was
significantly inhibited by Spongionella compounds pre-treatments
(p < 0.05). In summary, the inhibition of CypA prevents the
chemotaxis of activated T lymphocytes, although in presence of
high extracellular levels of CypA or B.DISCUSSION
In the present study, activated human T lymphocytes were used.
It is known that Con A, a plant lectin, has proinflammatory
properties and through the antigen receptor activates T
lymphocytes. Moreover, Con A stimulates the expression andA B C
D E F
FIGURE 3 | Effect of compounds 1, 2, and GraL over intra and extracellular CypA, B and C levels in human T lymphocytes stimulated with Con A Cells were pre-
treated with compound 1, 2 (0.1 µM), GraL (1 mM) or CsA (0.2 µM) for 2 h and then were stimulated with Con A (50 mg/mL) for 48 h. CypA (A), CypB (B), and CypC
(C) levels were measured by ELISA in the medium of T lymphocytes. The line represents the unstimulated cells values. The intracellular expression of CypA (D),
CypB (E), and CypC (F) was measured by western blot in cytosolic lysates of T lymphocytes. Band intensity was normalized by b-actin. Data are the result of
average ± SEM (n = 3). The values are shown as the difference between cells treated with Con A and cells treated with compounds plus Con A, *p < 0.05, **p <
0.01 and ***p < 0.001. Values of cells treated with Con A were compared with control cells, #p < 0.05, ##p < 0.01 and ###p < 0.001. One-way ANOVA test with
Dunnet’s post hoc analysis and Student´s t-test were used for statistical analysis.March 2021 | Volume 12 | Article 609196
Gegunde et al. CypA, B and C Rolerelease of CypA, as well as the migration of T cells (20, 26).
Furthermore, the release of CypB and C and their intracellular
levels were also increased in Con A-activated T cells, as described
for the first time in this work. Therefore, in addition to the well-
known CypA, CypB and C are also released by activated T
lymphocytes and play an important role in the inflammatory
process, either directly or indirectly. It is important to point out
that, while intracellular CypA and B are present in the cytosol,
intracellular CypC has a different localization, since lysates of
microsomal fractions containing the ER and Golgi apparatusFrontiers in Immunology | www.frontiersin.org 7were necessary to detect this immunophilin. CypC has been
associated with the ER in kidney and human hepatoma cells (32–
34). Therefore, from our findings, CypC is linked with the ER in
human T lymphocytes whereas CypA and B with the cytosol, and
all three are released to the extracellular media from these cells
upon inflammatory conditions.
As it was mentioned before, CypA seems to play a key role in
inflammatory processes, therefore, it was proposed as an
appropriate goal in these pathologies. In this sense, CsA was
used in several in vitro studies to modulate CypA (35). TheA
B
FIGURE 4 | Effect of compounds 1, 2, and GraL over plasma membrane levels of CD147 receptor in human T lymphocytes stimulated with Con A Cells were
pre-treated with compound 1, 2 (0.1 µM), GraL (1 mM) or CsA (0.2 µM) for 2 h and then were stimulated with Con A (50 mg/mL) for 48 h. Representative cellular
images of the expression of plasma membrane CD147 receptor: brightfield images are shown in channel 4 and FITC intensity images are presented on channel 2
(A). Histogram of the expression of plasma membrane CD147 receptor (B). Data are the result of average ± SEM (n = 3). The values are shown as the difference
between cells treated only with Con A and compared to cells treated with compounds plus Con A, **p < 0.01 and ***p < 0.001. Values of cells treated with Con A
were compared with control cells, ###p < 0.001. One-way ANOVA test with Dunnet’s post hoc analysis and Student´s t-test were used for statistical analysis.March 2021 | Volume 12 | Article 609196
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a ternary complex with CypA and calcineurin. This complex
blocks the activation of the nuclear factor of activated T cells
(NFAT) calcineurin-dependent, causing the impossibility of T cell
of reacting upon sternal stimuli (36). Besides, the inhibition of T
cell activation avoids the following cytokine production (2).
Nevertheless, CsA causes toxicity over the pancreas, central
nervous system, and kidney and it has been related to
hypertension and diabetes (37, 38). Moreover, when human
embryonic kidney and human hepatoma cell lines were treated
with CsA, the release of CypA, B and C were augmented (27, 39).
Natural gracilins showed anti-inflammatory capacities by their
affinity to CypA (22). Besides, they can modify transcriptional
factors and reduce IL-2 release in activated T cells by blocking the
activity of calcineurin phosphatase and inhibit CypA release (20,
22, 27). Moreover, it was recently reported that synthetic GraA-
derivatives reduce the release of inflammatory mediators, avoid
the translocation to the nucleus of inflammatory target proteins
and promote antioxidative mechanisms in activated BV2 cells,
likely through the CypA modulation (25). In the present paper,
GraL and two GraA-derivatives, compounds 1 and 2, with high
CypA affinity, in the CsA range, were chosen. These compounds
reduce CypA release and the expression of CypA and CD147
receptors in T cells. CypA reduction data reinforce the specific
affinity of compounds over this protein described earlier (21, 25).
However, although they show similar CypA affinities, they have
different effects on inflammatory hallmarks related to CypA (IL-2
release and calcineurin activity). This could explain the diverse
inhibition observed in CypA release.
On the other hand, the expression of CD147 surface membrane
receptor is upregulated by inflammation and by the modulation of
intracellular CypA (20, 40). In this sense, a CypA binding site
located in the transmembrane domain at the residue Pro211 of
CD147 is responsible for the receptor transport to the surface. The
transport and the expression of the surfacemembrane receptor were
greatly reduced after CsA treatments (41). Therefore, the decrease ofFrontiers in Immunology | www.frontiersin.org 8CD147 receptor expression observed in the presence of
Spongionella-derived compounds could be mediated by direct
interaction with intracellular CypA (21, 25). Recent data
demonstrate that proinflammatory neutrophils, monocytes and
leukocytes, and activated T cells when they were treated with an
anti-CD147 monoclonal antibody, missed their capability to
migrate in the presence of CypA. Furthermore, it has been
reported successful treatments for inflammatory processes are
based on the blockage of CD147 activity (42). In addition, the
decrease in the expression of the surface membrane receptor-
mediated by the depletion of intracellular CypA is also important
in the reduction of T cell migration observed by these compounds.
It should also be noted that if compounds can prevent T lymphocyte
migration, they could also prevent neutrophil and monocytes
migration, critical cells in the inflammatory response.
Besides the intracellular relevance of CypA in protein folding,
trafficking, and signaling functions, extracellular CypA has also
an important role. Extracellular CypA is a pro-inflammatory
cytokine that fosters inflammation in several cells. Not only
promotes leukocyte migration but stimulates the release of IL-1b,
IL-6, and IL-8, among others, in macrophages and monocytes
(43). The proliferation and migration of vascular smooth muscle
cells, as well as the matrix metalloproteinase activation, is
promoted by extracellular CypA. This immunophilin also
induces the apoptosis of endothelial cells, the expression of
adhesion molecules, and stimulates the platelet adhesion and
the atheromatous plaque formation in atherosclerosis (6, 28).
Furthermore, it has been demonstrated that in several cell types,
the activation of NF-kB, ERK1/2, JNK, Akt, and p-38 MAPK are
stimulated by extracellular CypA (6, 28). In addition,
extracellular CypB seems to have an important function as an
intercellular mediator in inflammation and enhances the
adhesion of platelets to collagen (44). Nevertheless, no data are
available about the functions of extracellular CypC in humans.
Therefore, the inhibition of CypA and B released by the
Spongionella-derived compounds could prevent inflammatoryA B
FIGURE 5 | Effect of compounds 1, 2, and GraL over human T lymphocytes migration. Cells were pre-treated with compound 1, 2 (0.1 µM), GraL (1 mM) or CsA
(0.2 µM) for 2 h and then were stimulated with Con A (50 mg/mL) for 48 h. Then, T cells were placed in the migration chamber for 24 hours in the presence of the
chemoattractant CypA (50 ng/mL) (A) or CypB (5 ng/mL) (B). Controls of untreated T cells in the presence or absence of Cyps are also included. Data are the result
of average ± SEM (n = 3). The values are shown as the difference between Con A migratory cell numbers compared to cells treated with compounds plus Con A,
*p < 0.05 and **p < 0.01. Values of cells treated with Con A were compared with cells in the presence of CypA or B, #p < 0.05. Values of untreated cells in absence
of CypA or B were compared with untreated cells in presence of CypA and B, +p < 0.05 or ++p < 0.01. One-way ANOVA test with Dunnet’s post hoc analysis and
Student´s t-test were used for statistical analysis.March 2021 | Volume 12 | Article 609196
Gegunde et al. CypA, B and C Roleresponses in several cell types, in addition to T cells. In this sense,
extracellular CypA and B are also interesting targets in the
modulation of chronic inflammatory diseases.
As aforementioned, CD147 is the receptor for extracellular
CypA and B, and their interactions are needed for cell response.
The extracellular receptor for CypC remains unidentified,
nevertheless, a binding site for CypC in the CD147 receptor has
been hypothesized (19). Therefore, the inhibition in the membrane
expression of this receptor could be the indirect cause of the CypB
and C reduction induced by Spongionella-derived compounds.
Although a direct effect over these immunophilins cannot be
discarded as well as the inhibition of their PPIase activity. In any
case, due to the reduction of intracellular Cyps and/or CD147
receptor, the migration of T cells and therefore, the infiltration of
them into the inflammatory site is blocked in the presence of
compounds. Consequently, these compounds were able to act over
the three Cyps associated with inflammatory-related diseases,
restoring Cyps levels up to control values. In this way, the
inflammatory pathway activated in some pathologies might be
avoided (45). Moreover, extracellular CypA and B act as
chemoattractant molecules. Therefore, the inhibition of T cell
migration in the presence of CypA and B by compounds could
block the subsequent inflammatory cascade (19). It should be also
taken into consideration that both CypA and B, in the present study,
stimulate the migration of resting T lymphocytes. Hence, by
inhibiting these stimuli, the migration and infiltration of
leukocytes could also be prevented in non-inflammatory
conditions. It is important to emphasize that CypC levels are also
reduced by Spongionella-derived compounds. This protein is highly
augmented in CAD, an inflammatory-related condition, therefore,
its direct or indirect modulation could be a useful therapeutic
strategy in inflammatory-based pathologies (4, 11, 13). Moreover,
the decrease in CypC expression and release are more evident in the
presence of compound 1 than compound 2 or GraL. This
discrepancy may point to different cell permeability, other
unknown cellular targets, or variances in their chemical structure.
Compound 1 is a regioisomer of 2, that is, it has a double bond in
the cyclohexene ring in a different position than compound 2 and
GraL (20, 21, 25). For these reasons, these compounds are proposed
in the present study as useful probe molecules to directly modulate
CypA and its receptor and to avoid the T lymphocyte migration.
Furthermore, in human activated T lymphocytes, the release
and intracellular expression of CypA, B, and C, as well as the
expression of the CD147 membrane receptor is upregulated and
can be modulated with known inhibitors. Extracellular CypA
and B are chemoattractants for activated T cells when these
proteins are increased within the cell.DATA AVAILABILITY STATEMENT
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